{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:35:14Z","timestamp":1793907314833,"version":"4.8.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40265-026-02322-0","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:45:19Z","timestamp":1777355119000},"page":"1153-1163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sonrotoclax: First Approval"],"prefix":"10.1007","volume":"86","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"issue":"1\u20132","key":"2322_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","volume":"28","author":"D Kaloni","year":"2023","unstructured":"Kaloni D, Diepstraten ST, Strasser A, et al. BCL-2 protein family: attractive targets for cancer therapy. Apoptosis. 2023;28(1\u20132):20\u201338.","journal-title":"Apoptosis"},{"issue":"10","key":"2322_CR2","doi-asserted-by":"publisher","first-page":"7836","DOI":"10.1021\/acs.jmedchem.4c00027","volume":"67","author":"Y Guo","year":"2024","unstructured":"Guo Y, Xue H, Hu N, et al. Discovery of the clinical candidate sonrotoclax (BGB-11417), a highly potent and selective inhibitor for both WT and G101V mutant Bcl-2. J Med Chem. 2024;67(10):7836\u201358.","journal-title":"J Med Chem"},{"key":"2322_CR3","unstructured":"BeOne Pharmaceutical (Suzhou) Co. Ltd. Sonrotoclax tablets: Chinese prescribing information. 2025. Accessed 9 Apr 2026."},{"key":"2322_CR4","unstructured":"BeOne Medicines. BeOne Medicines' novel BCL2 inhibitor, sonrotoclax, achieves first-in-world approval in R\/R MCL and R\/R CLL\/SLL [media release]. 6 Jan 2026. https:\/\/ir.beonemedicines.com\/news\/beone-medicines-novel-bcl2-inhibitor-sonrotoclax-achieves-first-in-world-approval-in-rr-mcl-and-rr-cllsll\/562da165-f6a9-48d0-a357-aca27ac112ca."},{"key":"2322_CR5","doi-asserted-by":"publisher","first-page":"7269","DOI":"10.1182\/blood-2022-169666","volume":"140","author":"H Quach","year":"2022","unstructured":"Quach H, Rajagopal R, Spencer A, et al. Preliminary safety of a BCL-2 inhibitor, BGB-11417, in patients with relapsed\/refractory multiple myeloma harboring t(11,14): a non-randomized, open-label, phase 1b\/2 study. Blood. 2022;140:7269\u201371.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2322_CR6","doi-asserted-by":"publisher","first-page":"5666","DOI":"10.1182\/blood-2025-5666","volume":"146","author":"SH Yi","year":"2025","unstructured":"Yi SH, Zhou KS, Liu N, et al. Primary analysis of a multicenter, open-label, phase 2 study of sonrotoclax (BGB-11417) monotherapy in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL) [abstract plus poster]. Blood. 2025;146(Suppl 1):5666\u20137.","journal-title":"Blood"},{"key":"2322_CR7","unstructured":"Cheah CY, Tam CS, Anderson MA, et al. Updated results from the phase 1 study of sonrotoclax (BGB-11417), a novel BCL2 inhibitor, in combination with zanubrutinib for relapsed\/refractory CLL\/SLL demonstrate deep and durable responses [abstract no. S159 plus poster no. 1514 plus presentation]. HemaSphere. 2025;9(Suppl 1):141\u20133."},{"key":"2322_CR8","unstructured":"Li C, Zhou K, Wei J, et al. Primary analysis results of novel BCL2 inhibitor sonrotoclax (BGB-11417) monotherapy in patients with relapsed\/refractory B-cell malignancies [poster no. PF574]. In: EHA2025 Congress. 2025."},{"issue":"Suppl 1","key":"2322_CR9","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1182\/blood-2025-793","volume":"146","author":"M Hoffmann","year":"2025","unstructured":"Hoffmann M, Ma S, Eradat H, et al. MRD-guided therapy of sonrotoclax (BGB-11417) + obinutuzumab (O) in patients with treatment-naive CLL: initial results from an ongoing phase 1\/1b study, BGB-11417-101 [abstract plus presentation]. Blood. 2025;146(Suppl 1):793\u20134.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2322_CR10","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1182\/blood-2025-3890","volume":"146","author":"J Soumerai","year":"2025","unstructured":"Soumerai J, Opat S, Cheah C, et al. Zanubrutinib plus obinutuzumab plus sonrotoclax in patients with treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma (TN CLL\/SLL): initial results from an ongoing phase 1\/1b study, BGB-11417-101 [abstract plus poster]. Blood. 2025;146(Suppl 1):3890\u20131.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2322_CR11","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1182\/blood-2025-3891","volume":"146","author":"C Tam","year":"2025","unstructured":"Tam C, Anderson MA, Lasica M, et al. Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: updated data from BGB-11417-101, an ongoing phase 1\/1b study [abstract plus poster]. Blood. 2025;146(Suppl 1):3891\u20132.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2322_CR12","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1182\/blood-2025-663","volume":"146","author":"MC Wang","year":"2025","unstructured":"Wang MC, Song YQ, Hermine O, et al. Sonrotoclax (BGB-11417) monotherapy in patients with relapsed\/refractory (R\/R) mantle cell lymphoma (MCL) previously treated with a bruton tyrosine kinase (BTK) inhibitor: early results from a phase 1\/2 study [abstract plus presentation]. Blood. 2025;146(Suppl 1):663\u20134.","journal-title":"Blood"},{"key":"2322_CR13","doi-asserted-by":"crossref","unstructured":"Tam CS, Opat S, Hoffmann M, et al. Combination treatment with novel BCL2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed\/refractory mantle cell lymphoma [abstract no. S234 plus poster no. DP003 plus presentation]. HemaSphere. 2025;9(Suppl 1):311\u20133.","DOI":"10.1002\/hon.70093_49"},{"issue":"Suppl 1","key":"2322_CR14","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2025-1809","volume":"146","author":"PQ Zhao","year":"2025","unstructured":"Zhao PQ, Zhou YL, Qiu LH, et al. Trium study: exploring MRD-guided triplet therapy with sonrotoclax, zanubrutinib, and CD20mab in untreated mantle cell lymphoma: a prospective, multicenter, phase II study [abstract]. Blood. 2025;146(Suppl 1):1809\u201310.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2322_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1182\/blood-2025-102","volume":"146","author":"H Quach","year":"2025","unstructured":"Quach H, Popat R, Chen WM, et al. Initial phase 1b\/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed\/refractory multiple myeloma [abstract plus presentation]. Blood. 2025;146(Suppl 1):102\u20133.","journal-title":"Blood"},{"key":"2322_CR16","doi-asserted-by":"crossref","unstructured":"Dhakal B, Hultcrantz M, Nathwani N, et al. Updated interim results of sonrotoclax plus dexamethasone in patients with t(11;14)-positive relapsed\/refractory multiple myeloma (R\/R MM): an all-oral treatment [abstract no. OA-60 plus poster no. PF721 plus presentation]. Clin Lymphoma Myeloma Leuk. 2025;25(Suppl 2):S41.","DOI":"10.1016\/S2152-2650(25)03464-0"},{"key":"2322_CR17","unstructured":"Jentzsch M, Shortt J, Fong CY, et al. Updated safety & antileukemic activity data of sonrotoclax (sonro; BGB-11417), a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in treatment-naive (TN) patients (pts) with acute myeloid leukemia (AML) unft for intensive chemotherapy [abstract no. V1101 plus poster no. PF477]. Oncol Res Treat. 2025;48(Suppl 2):139."},{"key":"2322_CR18","unstructured":"Wendtner CM, Cheah CY, Tam CS, et al. Updated safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed\/ refractory Waldenstr\u00f6m macroglobulinemia (R\/R WM) [abstract no. V315 plus poster no. PF887]. Oncol Res Treat. 2025;48(Suppl 2):64\u20135."},{"issue":"Suppl 1","key":"2322_CR19","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood-2025-2137","volume":"146","author":"O Al-Sawaf","year":"2025","unstructured":"Al-Sawaf O, Robrecht S, Davids MS, et al. A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL-RR1\/CELESTIAL-RRCLL) [abstract plus poster]. Blood. 2025;146(Suppl 1):2137\u20138.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2322_CR20","doi-asserted-by":"publisher","first-page":"3257.1","DOI":"10.1182\/blood-2024-198737","volume":"144","author":"PEM Patten","year":"2024","unstructured":"Patten PEM, Kater AP, Woyach JA, et al. CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naive CLL. Blood. 2024;144(Suppl 1):3257.1-.2.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2322_CR21","doi-asserted-by":"publisher","first-page":"1875.1","DOI":"10.1182\/blood-2024-201175","volume":"144","author":"S Yi","year":"2024","unstructured":"Yi S, Wang T, Li F, et al. Spruce-TN CLL\/SLL (cwCLL-002 study): an ongoing study of MRD-guided sonrotoclax plus zanubrutinib in treatment-na\u00efve chronic lymphocytic leukemia \/small lymphocytic lymphoma (CLL\/SLL). Blood. 2024;144(Suppl 1):1875.1-.2.","journal-title":"Blood"},{"key":"2322_CR22","doi-asserted-by":"crossref","unstructured":"Dreyling M, Hughes M, Eyre TA, et al. BGB-11417-302, a phase 3, randomized, doubleblind study of sonrotoclax (BGB11417) + zanubrutinib versus placebo + zanubrutinib in relapsed\/refractory mantle cell lymphoma [abstract no. OT03 plus presentation]. Hematol Oncol. 2025;43(Suppl 3):135\u20136.","DOI":"10.1002\/hon.70093_OT03"},{"issue":"Suppl 1","key":"2322_CR23","doi-asserted-by":"publisher","first-page":"1661.1","DOI":"10.1182\/blood-2024-198728","volume":"144","author":"HP Lee","year":"2024","unstructured":"Lee HP, Opat SS, Hrom J, et al. BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenstr\u00f6m macroglobulinemia [abstract plus poster]. Blood. 2024;144(Suppl 1):1661.1-.2.","journal-title":"Blood"},{"issue":"8","key":"2322_CR24","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1080\/14796694.2025.2469487","volume":"21","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Wu M, Jin Z, et al. Risk-stratified treatment of sonrotoclax with chemotherapy in newly diagnosed acute myeloid leukemia: a study protocol. Future Oncol. 2025;21(8):953\u20138.","journal-title":"Future Oncol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02322-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02322-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02322-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:39:35Z","timestamp":1782196775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02322-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2322"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02322-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah Blair is a salaried employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}